
Psychedelics biotech company Clearmind Medicine Inc. (OTC:CMNDF) has published information pertaining to the safety and efficacy of its flagship molecule, called MEAI or CMND-100, after its pre-IND meeting with the Food and Drug Administration on Wednesday.
MEAI is a proprietary psychedelic compound developed by Clearmind. The company is pushing to test the molecule in humans in order to assess its efficacy in the treatment of alcohol abuse disorder.